Tuesday, 11 September 2007
The following notices were given:
That, in accordance with section 5 of the Parliament Act 1974, the House approves the following proposal for work in the Parliamentary Zone which was presented to the House on 11 September 2007, namely: Humanities and Science Campus Square, Stage 1.
That the House:
- the ongoing persecution and suffering of Assyrians, Chaldeans, Mandaeans and other religious minorities in Iraq;
- the mass exodus of Christians and Mandaeans from Iraq to flee persecution; and
- the resolution of the United States House of Representatives to allocate at lease $10 million in emergency funds for the religious minorities of the Nineveh Plains; and
- calls on the Government in the strongest possible terms to lobby for better protection for Christians and Mandaeans in Iraq and also calls on the Government to closely examine the decision of the United States House of Representatives, with a view to increasing humanitarian assistance to the persecuted Christian and Mandaean minorities.
That the House:
- that Australia has the reported highest rate of mesothelioma in the world;
- that there has been a four to five-fold increase in the rate of mesothelioma since the early 1980s and that it is estimated that this rate will continue to increase for the next five to ten years;
- the chemotherapy agent Alimta is the only treatment registered for use in mesothelioma, and in combination with Cisplatin, represents the ‘gold standard’ for mesothelioma treatment in Australia;
- treatment by Alimta can significantly increase a patient’s survival time as well as improve a patient’s quality of life in its final stages;
- Alimta is listed on the Pharmaceutical Benefits Scheme (PBS) for persons who have contracted lung cancer for smoking, but is not approved for patients with mesothelioma;
- access to Alimta for mesothelioma patients is currently inequitable across Australia, with some States and companies providing various schemes to compensate victims of asbestos exposure and some patients having to pay for Alimta privately at great expense; and
- the UK National Institute for Health and Clinical Excellence recently approved the use of Alimta in the treatment of mesothelioma sufferers and the governments of France, Sweden and Japan subsidise the drug for sufferers in those countries; and
- calls on the Government to take all necessary action to support the inclusion of Alimta on the PBS for the treatment of all mesothelioma sufferers.